Fundraising Fox
Cambridge Epigenetix
Cambridge · Founded 2012 · United Kingdom corporation · 89 employees on LinkedIn · 8 known investors
Find your way into Cambridge Epigenetix
Sign up to see every warm intro you have to Cambridge Epigenetix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cambridge Epigenetix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.
Founders & leadership
Board
Investors · 8
How we know: Third Point Ventures's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: funding news · globenewswire.com · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: globenewswire.com · Not right? Tell us
How we know: globenewswire.com · Not right? Tell us
Funding
SEC filings, press & company announcements$100.3M disclosed across 2 rounds · 2018–2021
- $88MSeries DNov 2021 · 2 sources
Temasek (lead), Ahren Innovation Capital, GV, New Science Ventures, Sequoia, Third Point
Source ↗
▶$12.3MraisedMay 2018 · 15 investors · BiotechnologyRule 506(b)
- Martin MurphyDirector
- Jason MelladExecutive Officer, Director
- Bobby Yerramilli-RaoDirector
- Alice Newcombe-EllisDirector
- Somasundaram SubramaniamDirector
- Timothy RinkDirector
- Thomas HulmeDirector
- Shankar BalasubramanianDirector
- Offering amount
- $12.3M
- Amount sold
- $12.3M
- First sale
- Apr 2018
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Cambridge Epigenetix do?
- The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.
- Who are Cambridge Epigenetix's investors?
- Cambridge Epigenetix's investors include Third Point Ventures, Ahren Innovation Capital, GV (Google Ventures), New Science Ventures, Sequoia Capital, Syncona, Temasek, Third Point.
- How much funding has Cambridge Epigenetix raised?
- Cambridge Epigenetix has disclosed $100.3M raised across 2 rounds.
- Where is Cambridge Epigenetix headquartered?
- Cambridge Epigenetix is headquartered in Cambridge.